NO20043580L - Quinazolinonderivater og deres bruk som CB agonister - Google Patents

Quinazolinonderivater og deres bruk som CB agonister

Info

Publication number
NO20043580L
NO20043580L NO20043580A NO20043580A NO20043580L NO 20043580 L NO20043580 L NO 20043580L NO 20043580 A NO20043580 A NO 20043580A NO 20043580 A NO20043580 A NO 20043580A NO 20043580 L NO20043580 L NO 20043580L
Authority
NO
Norway
Prior art keywords
agonists
quinazolinone derivatives
quinazolinone
derivatives
Prior art date
Application number
NO20043580A
Other languages
English (en)
Other versions
NO20043580D0 (no
NO328305B1 (no
Inventor
Christopher Thomas Brain
Edward Karol Dziadulewicz
Terance William Hart
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0202755A external-priority patent/GB0202755D0/en
Priority claimed from GB0213285A external-priority patent/GB0213285D0/en
Priority claimed from GB0221459A external-priority patent/GB0221459D0/en
Priority claimed from GB0221460A external-priority patent/GB0221460D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20043580D0 publication Critical patent/NO20043580D0/no
Publication of NO20043580L publication Critical patent/NO20043580L/no
Publication of NO328305B1 publication Critical patent/NO328305B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20043580A 2002-02-06 2004-08-27 Kinazolinonderivater, fremgangsmate for fremstilling og en farmasoytisk sammensetning omfattende disse NO328305B1 (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0202755A GB0202755D0 (en) 2002-02-06 2002-02-06 Organic compounds
GB0213285A GB0213285D0 (en) 2002-06-10 2002-06-10 Organic compound
GB0221459A GB0221459D0 (en) 2002-09-16 2002-09-16 Organic compound
GB0221460A GB0221460D0 (en) 2002-09-16 2002-09-16 Organic compound
PCT/EP2003/001140 WO2003066603A1 (en) 2002-02-06 2003-02-05 Quinazolinone derivatives and their use as cb agonists

Publications (3)

Publication Number Publication Date
NO20043580D0 NO20043580D0 (no) 2004-08-27
NO20043580L true NO20043580L (no) 2004-09-21
NO328305B1 NO328305B1 (no) 2010-01-25

Family

ID=27739227

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043580A NO328305B1 (no) 2002-02-06 2004-08-27 Kinazolinonderivater, fremgangsmate for fremstilling og en farmasoytisk sammensetning omfattende disse

Country Status (21)

Country Link
US (2) US20050085493A1 (no)
EP (2) EP2319839A1 (no)
JP (2) JP4428479B2 (no)
KR (1) KR100954626B1 (no)
CN (1) CN100579968C (no)
AR (1) AR038483A1 (no)
AT (1) ATE551329T1 (no)
AU (1) AU2003210212A1 (no)
BR (1) BR0307461A (no)
CA (1) CA2471974C (no)
CO (1) CO5601021A2 (no)
EC (1) ECSP045219A (no)
ES (1) ES2384967T3 (no)
MX (1) MXPA04007641A (no)
MY (1) MY143958A (no)
NO (1) NO328305B1 (no)
NZ (1) NZ571615A (no)
PE (1) PE20030867A1 (no)
PL (1) PL370657A1 (no)
TW (1) TW200306839A (no)
WO (1) WO2003066603A1 (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU761453B2 (en) 1999-03-17 2003-06-05 Astrazeneca Ab Amide derivatives
TW200306839A (en) 2002-02-06 2003-12-01 Novartis Ag Quinazolinone derivatives and their use as CB agonists
GB0324790D0 (en) * 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives
CN1875021A (zh) 2003-11-04 2006-12-06 默克公司 取代的萘啶酮衍生物
SE0303491D0 (sv) * 2003-12-19 2003-12-19 Astrazeneca Ab New use VI
CN100506802C (zh) * 2004-06-04 2009-07-01 中国科学院上海药物研究所 一类甲酰肽样受体-1调节剂、其制备方法和用途
GB0413618D0 (en) * 2004-06-17 2004-07-21 Novartis Ag Organic compounds
US20090029984A1 (en) * 2005-07-11 2009-01-29 N.V. Organon Synergistic combination for the treatment of pain (cannabinoid receptor agonist and opioid receptor agonist)
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
WO2008157500A1 (en) * 2007-06-17 2008-12-24 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
FR2944013B1 (fr) * 2009-04-07 2011-07-15 Sanofi Aventis Derives de 1-alkyl-cinnolin-4(1h)-one substitues,leur preparation et leur application en therapeutique.
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
JP2013518085A (ja) 2010-02-01 2013-05-20 ノバルティス アーゲー ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
CA2867043A1 (en) 2012-05-03 2013-11-07 Novartis Ag L-malate salt of 2,7-diaza-spiro[4.5]dec-7-yle derivatives and crystalline forms thereof as ghrelin receptor agonists
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
CN106146414A (zh) * 2016-07-07 2016-11-23 浙江大学 喹唑啉二酮类衍生物及其制备方法和用途
CN106831502A (zh) * 2017-03-13 2017-06-13 苏州市泽宸贸易有限公司 邻硝基苯磺酰氯、其合成方法及应用
CN109796360B (zh) * 2019-01-30 2022-03-18 上海阿拉丁生化科技股份有限公司 一种3-氨基-2-萘甲酸类化合物的制备工艺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6200M (no) 1967-04-18 1968-07-22
DE1803210A1 (de) 1968-10-16 1970-05-14 Troponwerke Dinklage & Co 2-Methyl-3-(3-[4-phenylpiperazinyl-(1)]-2-hydroxypropyl)-chinazolinon-(4) und Verfahren zu seiner Herstellung
JPS5657768A (en) * 1979-10-18 1981-05-20 Masayuki Ishikawa Novel 4-quinazolone derivative substituted by aromatic residue at 3-position
NZ192392A (en) * 1978-12-19 1983-02-15 M Ishikawa 3-(substituted (phenyl or pyridyl)) -3,4-dihydroquinazolin-4-ones
JPS57118570A (en) * 1981-01-16 1982-07-23 Masayuki Ishikawa Novel 3-phenyl-4-quinazolone derivative
AU543928B2 (en) * 1981-01-16 1985-05-09 Masayuki Ishikawa 4(311)-quinazolinone derivatives
CA2131101A1 (en) * 1992-05-13 1993-11-25 Louis Desantis Jr. Topical ophthalmic compositions comprising a combination of calcium antagonists with known antiglaucoma agents
WO1997029079A1 (en) 1996-02-06 1997-08-14 Japan Tobacco Inc. Novel compounds and pharmaceutical use thereof
TW200306839A (en) 2002-02-06 2003-12-01 Novartis Ag Quinazolinone derivatives and their use as CB agonists
SE0303491D0 (sv) 2003-12-19 2003-12-19 Astrazeneca Ab New use VI
GB0413618D0 (en) * 2004-06-17 2004-07-21 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
US20070265285A1 (en) 2007-11-15
ATE551329T1 (de) 2012-04-15
KR20040083501A (ko) 2004-10-02
BR0307461A (pt) 2004-11-09
US20050085493A1 (en) 2005-04-21
AU2003210212A1 (en) 2003-09-02
PL370657A1 (en) 2005-05-30
ES2384967T3 (es) 2012-07-16
CN1628104A (zh) 2005-06-15
EP1472234A1 (en) 2004-11-03
CO5601021A2 (es) 2006-01-31
KR100954626B1 (ko) 2010-04-27
US8552015B2 (en) 2013-10-08
CA2471974C (en) 2011-11-22
TW200306839A (en) 2003-12-01
JP2005522439A (ja) 2005-07-28
EP1472234B1 (en) 2012-03-28
PE20030867A1 (es) 2003-12-04
MY143958A (en) 2011-07-29
CN100579968C (zh) 2010-01-13
CA2471974A1 (en) 2003-08-14
AR038483A1 (es) 2005-01-19
NZ571615A (en) 2010-01-29
NO20043580D0 (no) 2004-08-27
JP4428479B2 (ja) 2010-03-10
NO328305B1 (no) 2010-01-25
WO2003066603A1 (en) 2003-08-14
EP2319839A1 (en) 2011-05-11
HK1079518A1 (zh) 2006-04-07
MXPA04007641A (es) 2004-11-10
ECSP045219A (es) 2004-09-28
JP2009149658A (ja) 2009-07-09

Similar Documents

Publication Publication Date Title
NO20026010D0 (no) Substituerte quinazolinderivater og deres anvendelse som inhibitorer
NO20043580L (no) Quinazolinonderivater og deres bruk som CB agonister
DK1480962T3 (da) 5-Phenylthiazol-derivater og deres anvendelse som P1-3-kinaseinhibitorer
DK1478629T3 (da) N-aryl-2-oxazolidinon-5-carboxamider og deres derivater og deres anvendelse som antibakterielle midler
NO20053356D0 (no) Aminindazolderivater og anvendelse derav som kinaseinhibitorer.
DK1956004T3 (da) Quinolinderivater og deres anvendelse som 5-HT6-ligander
DK1480955T3 (da) O-cyclopropyl-carboxanilider og deres anvendelse som fungicider
DK1527050T3 (da) Quinolin-derivater og deres anvendelse som mycobakterielle inhibitorer
DK1578755T3 (da) Phosphonooxyguinalinderivater og deres farmaceutiske anvendelse
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
DK1499311T3 (da) Substituerede benzaboler og anvendelse deraf som RAF-kinaseinhibitorer
DK1558615T3 (da) Purin-forbindelser og deres anvendelse som cannabinoid receptor ligander
NO20044137L (no) Aminoindazolderivater, deres fremstilling og anvendelse samt mellomprodukter
DK1368349T3 (da) Xanthinderivater, deres fremstilling og deres anvendelse som lægemidler
DK1581532T3 (da) Pyrazolo-3,4-B pyridinforbindelser og deres anvendelse som phosphodiesterase inhibitorer
DK1761529T3 (da) Pyrrolopyridinderivater og deres anvendelse som CRTh2-antagonister
DK1539712T3 (da) Pyrimidinderivater og deres anvendelse som CB2-modulatorer
DK1133477T3 (da) Substituerede benzimidazoler og deres anvendelse som parpinhibitorer
DK1455785T3 (da) Substituerede 2-thio-3,5-dicyano-4-phenyl-6-aminopyridiner og deres anvendelse
NO20031952L (no) 3-aroylinderivater og deres anvendelse som CB2 reseptoragonister
NO20042719L (no) Substituerte 2-amino-cykloalkankarboksamider og deres anvendelse som protease-inhibitorer
DK1581518T3 (da) Substituerede 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazin-derivater og deres anvendelse som neurokinin antagonister
NO20050665L (no) Pyrrolidonderivater som MAOE inhibitoere
NO20043349L (no) Kumarinderivater, fremgangsmate for deres framstilling og anvendelse derav
DK1387838T3 (da) Cyanoanthranylamid-derivater og deres anvendelse som lægemidler

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees